Fosaprepitant Dimeglumine 150mg
Product Overview
| Generic Name | Fosaprepitant Dimeglumine 150mg |
| Brand Name(s) | Emend® IV, IVEMEND® |
| Category | Antineoplastic / Cancer |
| Form | Vial, Sterile lyophilised powder for solution for injection/infusion |
| Strength | 150 mg |
| Therapeutic Class | Antiemetic; neurokinin-1 receptor antagonist / substance P antagonist |
| ATC Code | A04AD12 |
Manufacturing & Regulatory
| Manufacturer | Merck, Accord Farma, Baxter |
| GMP Compliance | WHO-GMP |
| DMF/CEP | Type II DMF |
| COFEPRIS | 010.000.6023.00 |
| Free Sale Certificate | Yes, available as COPP/CPP |
Logistics & Export
| MOQ | 10 Vials |
| Shelf Life | 24 Months |
| Storage | refrigerated 2°C–8°C; do not freeze; |
| Incoterms | EXW, HS/HSN 30049099 |
| Lead Time | 7 - 10 Business Days |
Documentation Available Upon Request
| Certificate of Analysis (PDF) | Supplied per batch upon request |
| CTD Summary (PDF) | CTD available to regulators; summary available to qualified partners |
Special Notes
(Fosaprepitant de dimeglumina)
Fosaprepitant de dimeglumina 150 mg is an intravenous neurokinin-1 receptor antagonist used in combination with other antiemetic agents, commonly a 5-HT3 antagonist and dexamethasone, for prevention of acute and delayed nausea and vomiting associated with highly or moderately emetogenic cancer chemotherapy.